CLINICALLY NONFUNCTIONING PITUITARY TUMOR

Definition and Overview

• Clinically Nonfunctioning Pituitary Tumors
  • Identified incidentally on head MRI or due to sellar mass–related symptoms (e.g., visual field defect).
  • Pituitary microadenomas (≤10 mm) are relatively common (found in ~11% of pituitary glands on autopsy), but macroadenomas (>10 mm) are much less common.

Histopathology and Origin

• Gonadotroph Cell Adenoma
  • Most frequent type of clinically nonfunctioning pituitary macroadenoma.
  • Usually do not hypersecrete gonadotropins (no hormone-excess syndrome).
• Null Cell (Chromophobe) Adenoma
  • Second most common nonfunctioning macroadenoma.
  • Benign neoplasm of adenohypophyseal cells staining negative for all anterior pituitary hormones on immunohistochemistry.
• Rare Silent Adenomas
  • Lactotroph, somatotroph, or corticotroph adenomas can be clinically silent (i.e., not producing symptoms of hormone excess).

CLINICAL PRESENTATION

Mass-Effect Symptoms of Pituitary Macroadenomas

• Visual Field Defects
  • Suprasellar extension → compression of the optic chiasm.
  • Gradual onset of superior bitemporal quadrantopia → can progress to bitemporal hemianopsia.
  • Vision loss may go unnoticed until it becomes significant.
• Diplopia
  • Extension into the cavernous sinus compresses cranial nerves controlling eye movements.
• Pituitary Insufficiency
  • Compression of normal pituitary gland tissue, leading to hypopituitarism.
• Headaches
  • Related to tumor expansion in the sellar region.

DIAGNOSIS AND EVALUATION

1. MRI
   • Imaging modality of choice to evaluate the sella and surrounding structures.
   • Shows the extent of suprasellar and parasellar extension of the macroadenoma.
2. Hormonal Assessment
   • Hyperprolactinemia (mild, typically 30–200 ng/mL) may be due to stalk compression inhibiting dopaminergic (prolactin-inhibitory) control of lactotrophs.
   • Other Pituitary Hormones to Measure in all patients with macroadenomas:
     • Luteinizing hormone (LH)
     • Follicle-stimulating hormone (FSH)
     • α-Subunit of glycoprotein hormones
     • Gonadal hormones (estrogen in women, testosterone in men)
     • Insulin-like growth factor 1 (IGF-1)
     • Corticotropin (ACTH) and cortisol
     • Thyrotropin (TSH) and free thyroxine (T4)
   • Diabetes Insipidus is rare with benign adenohypophyseal tumors.
3. Visual Field Examination
   • Assess for bitemporal hemianopsia or other defects if the tumor is large or close to the optic chiasm.

TREATMENT

Goals

• Relieve Mass-Effect Symptoms (e.g., vision loss).
• Preserve Pituitary Function.

Management Options

1. Observation
   • Reasonable for elderly patients with normal visual fields and small or stable tumors.
2. Transsphenoidal Surgery
   • Recommended for patients with vision loss or progressive tumor growth.
   • Can provide prompt resolution of visual field defects and potentially cure the tumor.
   • Some patients experience recovery of preoperative pituitary insufficiency post-surgery.
3. Radiotherapy (e.g., Stereotactic Gamma Knife)
   • Considered if the adenoma recurs after transsphenoidal surgery or if surgery is incomplete.
   • Postoperative MRI is typically performed ~3 months after surgery to assess resection extent and tumor status.

POSTOPERATIVE FOLLOW-UP

• MRI Surveillance
  • Usually repeated 3 months after surgery, then periodically to detect early recurrence.
• Hormone Levels
  • Check any previously elevated tumor markers (e.g., α-subunit) or other hormone abnormalities.
• Long-Term Management
  • Recurrence can be treated with further surgery or stereotactic radiotherapy.